Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4659 Current role of systemic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) sporadic and hereditary

Introduction: Retrospective, performed in prospective manner single-arm, open-label, case series study to assess the efficacy of lanreotide in patients with unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations.

Conference:

Presenting Author:

Authors: Kolasińska-Ćwikla A, Pęczkowska M, Michałowska I, Pałucki J, Roszkowska-Purska K,

Keywords: Paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations, Lanreotide therapy, fractionated metoxycatecholamines,

#3039 Evaluation of Overall Survival (OS) in Patients with NETG1/G2 Neuroendocrine Neoplasms of the Small Intestine (SI-NENs)

Introduction: In many cases, the cause of death in patients with carcinoid syndrome (CS) is carcinoid heart disease (CHD) which is most often diagnosed in patients with SI-NEN.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Ćwikła J

Authors: Konsek-Komorowska S, Pęczkowska M, Kolasińska-Ćwikła A, Cichocki A, Roszkowska-Purska K,

Keywords: Neuroendocrine Neoplasms of the Small Intestine, SI-NENs, carcinoid syndrome, carcinoid heart disease, Overall Survival,

#2300 Clinical Use of Lanreotide AG as Initial Therapy in Patients with Advanced, Non-Resectable Well (G1) and Moderate (G2) Differentiated Pancreatic Neuroendocrine Neoplasms (p-NEN)

Introduction: Lanreotide AG currently is used as standard initial therapy in NETG1 & G2 pancreatic NEN with Ki-67

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Cwikla J

Authors: Ćwikła J, Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Pałucki J, Roszkowska-Purska K,

Keywords: advance, non-resectable pancreatic neuroendocrine neoplams, Lanreotide AG systemic therapy,

#2290 PRRT in Hindgut and Cancer of Unknown Primary NEN

Introduction: There are limited data regarding PRRT in hindgut and CUP (cancer of unknown primary).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Ćwikla J

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Cichocki A, Roszkowska-Purska K, Dobkowski P,

Keywords: NENs, PRRT, Hindgut, CUP,

#2268 Efficacy of Octreotide LAR in Treatment of Naive Patients with Advanced, Non-Resectable Well and Moderate Differentiated Pancreatic Neuroendocrine Neoplasms (p-NENs)

Introduction: SSA are the first line therapy in well differentiated pNET

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kolasińska-Ćwikla A

Authors: Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Bednarczuk T, Pałucki J, Roszkowska-Purska K,

Keywords: advance, non-resectable pancreatic neuroendocrine neoplams, Octreotide LAR therapy,